Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma

Introduction Osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regimen for these patients. Method and materials We investigated 15 patients aged 15 to 40 years old and used continuous infusion of cisplatin, doxorubicin intermittently with ifosfamide, doxorubicin as neoadjuvant chemotherapy. Percent of necrosis and toxicities was recorded for each patient. Results Out of 15 patients investigated, 13 were males and 2 females. Tumor necrosis≥ 90% (defined as good necrosis) was observed in 60% of patients. 26.7% of the patients showed leucopenia grade three or four, 26.7% had anemia grade three or four, and 20% showed thrombocytopenia grade three or four. Conclusion The above chemotherapy regimen can cause as good necrosis as the chemotherapy regimens including high dose of MTX with reduced toxicity and less nursing cares and laboratory tests. Of course small sample size limits extension of our result to all patients but trying this regimen is recommended in more patients to see more reliable results.

[1]  David M. Thomas,et al.  Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Yoshikawa,et al.  Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan , 2013, Journal of chemotherapy.

[3]  S. Ferrari,et al.  Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. S. Hall,et al.  High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. , 2012, British journal of clinical pharmacology.

[5]  H. Gelderblom,et al.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? , 2011, European journal of cancer.

[6]  N. Daw,et al.  Frontline treatment of localized osteosarcoma without methotrexate , 2011, Cancer.

[7]  K. Mahadeo,et al.  Ambulatory high‐dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost‐effective , 2010, Pediatric blood & cancer.

[8]  N. Daw,et al.  Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. de Camargo,et al.  Methotrexate for high-grade osteosarcoma in children and young adults. , 2009, The Cochrane database of systematic reviews.

[10]  M. Devidas,et al.  P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial , 2004 .

[11]  M. Devidas,et al.  P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Link,et al.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Ferrari,et al.  Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Shuster,et al.  Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. , 1991, Clinical orthopaedics and related research.

[15]  A. Giuliano,et al.  Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[17]  G. Rosen Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. , 1985, Orthopedics.